Bausch + Lomb and Nicox’s Glaucoma Candidate VESNEO® (latanoprostene bunod) Meets Primary Endpoint in Phase 3 Studies

September 24, 2014

← Back to blog page

Cookies

By continuing to use this website, you agree to our Cookie Policy.